BACKGROUND: Emerging evidences have gradually revealed the skeletal muscle attenuation (MA) was not only reflected the accumulation of lipids in skeletal muscle but also associated with physiological and pathological states. The aim of this study was to evaluate the impact of MA on the prognosis of pancreatic cancer patients treated with neoadjuvant chemoradiotherapy (NACRT). METHODS: Eighty-three patients with pancreatic cancer who received NACRT were enrolled. Patients were divided according to their Hounsfield units of the skeletal muscle at the third lumbar vertebra in CT. The lower quartile was defined as MA group and the remainder as control group. RESULTS: There was no significant difference in overall survival between pre-NACRT MA and control groups. In contrast, patients with post-NACRT MA had a significantly poorer prognosis than patients without. The patients in the post-NACRT MA group were significantly older than patients in the control group. There were no significant differences in most clinicopathological and perioperative factors between both groups. However, patients with post-NACRT MA had a longer hospital stay than patients without. Furthermore, the incompletion rate of the proposed adjuvant chemotherapy was significantly higher in the MA group than control. Importantly, multivariate analysis indicated that post-NACRT MA was an independent prognostic factor. CONCLUSIONS: Muscle attenuation may have a significant impact in pancreatic cancer patients treated with multimodal therapy. Therefore, our data may provide new insights into perioperative patient care to improve the prognosis of resectable pancreatic cancer.
BACKGROUND: Emerging evidences have gradually revealed the skeletal muscle attenuation (MA) was not only reflected the accumulation of lipids in skeletal muscle but also associated with physiological and pathological states. The aim of this study was to evaluate the impact of MA on the prognosis of pancreatic cancerpatients treated with neoadjuvant chemoradiotherapy (NACRT). METHODS: Eighty-three patients with pancreatic cancer who received NACRT were enrolled. Patients were divided according to their Hounsfield units of the skeletal muscle at the third lumbar vertebra in CT. The lower quartile was defined as MA group and the remainder as control group. RESULTS: There was no significant difference in overall survival between pre-NACRT MA and control groups. In contrast, patients with post-NACRT MA had a significantly poorer prognosis than patients without. The patients in the post-NACRT MA group were significantly older than patients in the control group. There were no significant differences in most clinicopathological and perioperative factors between both groups. However, patients with post-NACRT MA had a longer hospital stay than patients without. Furthermore, the incompletion rate of the proposed adjuvant chemotherapy was significantly higher in the MA group than control. Importantly, multivariate analysis indicated that post-NACRT MA was an independent prognostic factor. CONCLUSIONS: Muscle attenuation may have a significant impact in pancreatic cancerpatients treated with multimodal therapy. Therefore, our data may provide new insights into perioperative patient care to improve the prognosis of resectable pancreatic cancer.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess Journal: JAMA Date: 2007-01-17 Impact factor: 56.272
Authors: Sami Antoun; Emilie Lanoy; Roberto Iacovelli; Laurence Albiges-Sauvin; Yohann Loriot; Mansouriah Merad-Taoufik; Karim Fizazi; Mario di Palma; Vickie E Baracos; Bernard Escudier Journal: Cancer Date: 2013-06-25 Impact factor: 6.860
Authors: D A Pan; S Lillioja; A D Kriketos; M R Milner; L A Baur; C Bogardus; A B Jenkins; L H Storlien Journal: Diabetes Date: 1997-06 Impact factor: 9.461
Authors: J Arends; G Bodoky; F Bozzetti; K Fearon; M Muscaritoli; G Selga; M A E van Bokhorst-de van der Schueren; M von Meyenfeldt; G Zürcher; R Fietkau; E Aulbert; B Frick; M Holm; M Kneba; H J Mestrom; A Zander Journal: Clin Nutr Date: 2006-05-12 Impact factor: 7.324
Authors: Juan W Valle; Daniel Palmer; Richard Jackson; Trevor Cox; John P Neoptolemos; Paula Ghaneh; Charlotte L Rawcliffe; Claudio Bassi; Deborah D Stocken; David Cunningham; Derek O'Reilly; David Goldstein; Bridget A Robinson; Christos Karapetis; Andrew Scarfe; Francois Lacaine; Juhani Sand; Jakob R Izbicki; Julia Mayerle; Christos Dervenis; Attila Oláh; Giovanni Butturini; Pehr A Lind; Mark R Middleton; Alan Anthoney; Kate Sumpter; Ross Carter; Markus W Büchler Journal: J Clin Oncol Date: 2014-01-13 Impact factor: 44.544
Authors: Candyce H Kroenke; Carla M Prado; Jeffrey A Meyerhardt; Erin K Weltzien; Jingjie Xiao; Elizabeth M Cespedes Feliciano; Bette J Caan Journal: Cancer Date: 2018-05-24 Impact factor: 6.860
Authors: Jordan M Cloyd; Graciela M Nogueras-González; Laura R Prakash; Maria Q B Petzel; Nathan H Parker; An T Ngo-Huang; David Fogelman; Jason W Denbo; Naveen Garg; Michael P Kim; Jeffrey E Lee; Ching-Wei D Tzeng; Jason B Fleming; Matthew H G Katz Journal: J Gastrointest Surg Date: 2017-12-11 Impact factor: 3.452
Authors: Gabriel F P Aleixo; Shlomit S Shachar; Kirsten A Nyrop; Hyman B Muss; Claudio L Battaglini; Grant R Williams Journal: Oncologist Date: 2019-11-12
Authors: Philippe Atlan; Mohamed Amine Bayar; Emilie Lanoy; Benjamin Besse; David Planchard; Jordy Ramon; Bruno Raynard; Sami Antoun Journal: Support Care Cancer Date: 2017-06-08 Impact factor: 3.603
Authors: Gabriel F P Aleixo; Shlomit S Shachar; Kirsten A Nyrop; Hyman B Muss; Claudio L Battaglini; Grant R Williams Journal: Oncologist Date: 2019-11-12 Impact factor: 5.837